346 related articles for article (PubMed ID: 16091056)
1. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
Caos A; Breiter J; Perdomo C; Barth J
Aliment Pharmacol Ther; 2005 Aug; 22(3):193-202. PubMed ID: 16091056
[TBL] [Abstract][Full Text] [Related]
2. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group.
Caos A; Moskovitz M; Dayal Y; Perdomo C; Niecestro R; Barth J
Am J Gastroenterol; 2000 Nov; 95(11):3081-8. PubMed ID: 11095321
[TBL] [Abstract][Full Text] [Related]
3. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years.
Thjodleifsson B; Rindi G; Fiocca R; Humphries TJ; Morocutti A; Miller N; Bardhan KD;
Aliment Pharmacol Ther; 2003 Feb; 17(3):343-51. PubMed ID: 12562446
[TBL] [Abstract][Full Text] [Related]
5. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group.
Thjodleifsson B; Beker JA; Dekkers C; Bjaaland T; Finnegan V; Humphries TJ
Dig Dis Sci; 2000 May; 45(5):845-53. PubMed ID: 10795744
[TBL] [Abstract][Full Text] [Related]
6. Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group.
Birbara C; Breiter J; Perdomo C; Hahne W
Eur J Gastroenterol Hepatol; 2000 Aug; 12(8):889-97. PubMed ID: 10958216
[TBL] [Abstract][Full Text] [Related]
7. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
Farley A; Wruble LD; Humphries TJ
Am J Gastroenterol; 2000 Aug; 95(8):1894-9. PubMed ID: 10950032
[TBL] [Abstract][Full Text] [Related]
8. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.
Miner P; Orr W; Filippone J; Jokubaitis L; Sloan S
Am J Gastroenterol; 2002 Jun; 97(6):1332-9. PubMed ID: 12094846
[TBL] [Abstract][Full Text] [Related]
9. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease.
Bytzer P; Blum A; De Herdt D; Dubois D;
Aliment Pharmacol Ther; 2004 Jul; 20(2):181-8. PubMed ID: 15233698
[TBL] [Abstract][Full Text] [Related]
10. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study.
Labenz J; Armstrong D; Lauritsen K; Katelaris P; Schmidt S; Schütze K; Wallner G; Juergens H; Preiksaitis H; Keeling N; Nauclér E; Adler J; Eklund S
Aliment Pharmacol Ther; 2005 Nov; 22(9):803-11. PubMed ID: 16225489
[TBL] [Abstract][Full Text] [Related]
11. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
Dekkers CP; Beker JA; Thjodleifsson B; Gabryelewicz A; Bell NE; Humphries TJ
Aliment Pharmacol Ther; 1999 Jan; 13(1):49-57. PubMed ID: 9892879
[TBL] [Abstract][Full Text] [Related]
12. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial.
Dickman R; Emmons S; Cui H; Sewell J; Hernández D; Esquivel RF; Fass R
Aliment Pharmacol Ther; 2005 Sep; 22(6):547-55. PubMed ID: 16167971
[TBL] [Abstract][Full Text] [Related]
13. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group.
Richter JE; Bochenek W
Am J Gastroenterol; 2000 Nov; 95(11):3071-80. PubMed ID: 11095320
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study.
Fass R; Delemos B; Nazareno L; Kao R; Xiang J; Lu Y
Aliment Pharmacol Ther; 2010 May; 31(9):950-60. PubMed ID: 20132154
[TBL] [Abstract][Full Text] [Related]
15. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
Robinson M; Fitzgerald S; Hegedus R; Murthy A; Jokubaitis L;
Aliment Pharmacol Ther; 2002 Mar; 16(3):445-54. PubMed ID: 11876697
[TBL] [Abstract][Full Text] [Related]
16. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Caro JJ; Salas M; Ward A
Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease.
van Zyl J; van Rensburg C; Vieweg W; Fischer R
Digestion; 2004; 70(1):61-9. PubMed ID: 15297779
[TBL] [Abstract][Full Text] [Related]
18. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
Wit NJ; Boer WA; Geldof H; Hazelhoff B; Bergmans P; Tytgat GN; Smout AJ
Aliment Pharmacol Ther; 2004 Aug; 20(4):451-8. PubMed ID: 15298640
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.
Holtmann G; Bytzer P; Metz M; Loeffler V; Blum AL
Aliment Pharmacol Ther; 2002 Mar; 16(3):479-85. PubMed ID: 11876701
[TBL] [Abstract][Full Text] [Related]
20. Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study.
Breiter JR; Riff D; Humphries TJ
Am J Gastroenterol; 2000 Apr; 95(4):936-42. PubMed ID: 10763941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
